Ping Rawson
Chief Financial Officer
Replay available
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call
Dyadic International, Inc. (NASDAQ: DYAI) Q2 2026 earnings conference call, held 2026-08-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Joe Hazelton
President and Chief Operating Officer
Mark Emalfarb
Chief Executive Officer
Matt Hewitt
Analyst, Craig-Hallum Capital Group
John Vandermosten
Analyst, Zacks
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Dyadic International, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.093 Good evening and welcome to Dyadic International's Q2 2026 00:00:05.093 -- 00:00:10.055 conference call. Currently, all participants are in the listen-only mode. 00:00:10.055 -- 00:00:15.217 Following management's prepared remarks, there will be a brief question and answer session. 00:00:15.217 -- 00:00:19.959 As a reminder, this conference call is being recorded today, August 12th, 2026. 00:00:19.959 -- 00:00:22.920 I would now like to turn the call over to Ms. 00:00:22.920 -- 00:00:26.122 Ping Rawson, Dyadic's Chief Financial Officer. 00:00:26.122 -- 00:00:28.502 Please go ahead. 00:00:28.703 -- 00:00:34.087 Thank you. Good evening and welcome everyone to DIATIC's second quarter 2026 00:00:34.087 -- 00:00:39.450 conference call. I hope you have had the opportunity to review DIATIC's press releases 00:00:39.450 -- 00:00:45.033 announcing financial results for the quarter ended June 30, 2026. 00:00:45.033 -- 00:00:49.996 You may access our release and form 10-Q under the investor session of the company's 00:00:49.996 -- 00:00:52.907 website at diatic.com. 00:00:52.907 -- 00:00:57.570 On today's call, our President and Chief Operating Officer, Joe Hazelton, will review 00:00:57.570 -- 00:01:02.993 our Q2 2026 business and corporate highlights and provide commentary 00:01:02.993 -- 00:01:06.115 on the strategic direction of the business. 00:01:06.115 -- 00:01:11.878 Our CEO, Mark Emalfarb, will provide an update on our biopharmaceutical program, 00:01:11.878 -- 00:01:17.081 and I will follow with a review of our financial results in more detail, after which 00:01:17.081 -- 00:01:21.398 we will hold a brief question and answer session. 00:01:21.398 -- 00:01:25.659 At this time, I would like to inform you that certain commentary made i...